|
| SUSA22 |
New Frontiers in NIH AIDS Research |
| |
Non-Commercial Satellite
|
| Venue: |
Session Room 6 |
| Time: |
22.07.2012, 11:15 - 13:15 |
|
Chair:
|
Jack Whitescarver, United States
|
| Organiser: |
U.S. National Institutes of Health (NIH)
|
| |
| |
| What are the biggest research challenges ahead in the effort to turn the tide against AIDS? How close are we to developing effective microbicides or vaccines? And is a cure for HIV infection really possible?
This interative satellite with leading researchers from the U.S. National Institutes of Health (NIH) will outline the most important advances and challenges in AIDS research to date, including efforts to develop:
*Better methods to prevent, identify and treat HIV and its co-infections, malignancies and complications
*Improved biomedical and behavioral prevention tools, including Treatment as Prevention, microbicides, pre-exposure prophylaxis (PrEP) and vaccines
*Strategies to understand the factors that affect HIV risk, treatment outcomes, and disease progression among different populations
*New treatment and prevention strategies for substance users
*Approaches to overcome drug resistance and treatment failure and to eradicate persistent HIV viral reservoirs, that may one day lead to a cure |
 Webcast provided by The Kaiser Family Foundation
|
11:15
Powerpoint | Welcome
J. Whitescarver, United States
| 11:20
Powerpoint | The NIH: Turning Discovery into Health
F. Collins, United States
| 11:30
Powerpoint | NIAID HIV/AIDS Research: Introduction and Overview
A. Fauci, United States
| 11:35
Powerpoint | NIAID AIDS Research: Achievements and Challenges
C. Dieffenbach, United States
| 11:50
Powerpoint | Understanding Neuro-AIDS and Implications for the Cure
A. Nath, United States
| 12:05
Powerpoint | Advances in Treating and Preventing HIV in Substances Users
N. Volkow, United States
| 12:20
Powerpoint | New Challenges in HIV-defining and Non-defining Malignancies
R. Yarchoan, United States
| 12:35
Powerpoint | Panel Discussion: Implications of Scientific Advances for Populations at Risk: Perspectives from Researchers, Clinicians, and the Community
V. Cargill, United States
B. Eldadah, United States
M. Harrington, United States
B. Kapogiannis, United States
| 12:35
| Panel Discussion: Implications of Scientific Advances for Populations at Risk: Perspectives from Researchers, Clinicians, and the Community
G. Brown, United States
| 12:55
| Questions and Answers
|
|
| Powerpoints presentations |
| Welcome - Jack Whitescarver | |
| The NIH: Turning Discovery into Health - Francis Collins | |
| NIAID HIV/AIDS Research: Introduction and Overview - Anthony Fauci | |
| NIAID AIDS Research: Achievements and Challenges - Carl W. Dieffenbach | |
| Understanding Neuro-AIDS and Implications for the Cure - A. Nath | |
| Advances in Treating and Preventing HIV in Substances Users - Nora Volkow | |
| New Challenges in HIV-defining and Non-defining Malignancies - R. Yarchoan | |
| Panel Discussion: Implications of Scientific Advances for Populations at Risk: Perspectives from Researchers, Clinicians, and the Community - | |
|
Rapporteur report
Track B report by Jose R Arribas
SUSA22. New Frontiers in NIH AIDS Research. SUSA22. (Non-Commercial Satellite)
This session was a very interesting overview of the priorities of NIH-funded research (more than 3 billion dollars for 2012). In 2012 this budget would be distributed:
Vaccines: 29.9%
Therapeutics: 26.2%
Etiology and Pathogenesis: 20.6%
Natural History and Epidemiology: 10.2%
Microbicides: 6%
Training & Infrastructure: 4.5%
Behavioral research: 1.8%
Information dissemination: 0.8%
The exciting areas of research that the speakers reviewed were:
Current key scientific challenges and major priorities:
- Vaccine
- Follow up on RV144 result*
- Advance broadly neutralizing antibodies into proof of concept
- Cure
- Understanding Neuro-AIDS and Implications for the Cure
- HIV, AIDS and substance abuse: the goal seek, test, treat and retain
* Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209–2220.
|
|